Literature DB >> 19265660

Mesenchymal stem cell homing: the devil is in the details.

Jeffrey M Karp1, Grace Sock Leng Teo.   

Abstract

The study of MSC trafficking is clinically relevant for minimally invasive cell therapy to promote regeneration of damaged tissue, to treat inflammation, and to promote angiogenesis. However, these studies are complicated by the diverse methods used to culture, characterize, and deliver MSCs and by the variety of methods used to assess homing events. This review provides a critical analysis of the methods used to track homing of exogenously infused MSCs and discusses strategies for enhancing their trafficking to particular tissues.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19265660     DOI: 10.1016/j.stem.2009.02.001

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN: 1875-9777            Impact factor:   24.633


  513 in total

1.  Allogeneic mesenchymal stem cells do not protect NZBxNZW F1 mice from developing lupus disease.

Authors:  M Youd; C Blickarz; L Woodworth; T Touzjian; A Edling; J Tedstone; M Ruzek; R Tubo; J Kaplan; T Lodie
Journal:  Clin Exp Immunol       Date:  2010-04-29       Impact factor: 4.330

Review 2.  Mesenchymal stem cells for the sustained in vivo delivery of bioactive factors.

Authors:  Todd Meyerrose; Scott Olson; Suzanne Pontow; Stefanos Kalomoiris; Yunjoon Jung; Geralyn Annett; Gerhard Bauer; Jan A Nolta
Journal:  Adv Drug Deliv Rev       Date:  2010-10-13       Impact factor: 15.470

3.  Guided migration of neural stem cells derived from human embryonic stem cells by an electric field.

Authors:  Jun-Feng Feng; Jing Liu; Xiu-Zhen Zhang; Lei Zhang; Ji-Yao Jiang; Jan Nolta; Min Zhao
Journal:  Stem Cells       Date:  2012-02       Impact factor: 6.277

4.  Engineered cell homing.

Authors:  Debanjan Sarkar; Joel A Spencer; Joseph A Phillips; Weian Zhao; Sebastian Schafer; Dawn P Spelke; Luke J Mortensen; Juan P Ruiz; Praveen Kumar Vemula; Rukmani Sridharan; Sriram Kumar; Rohit Karnik; Charles P Lin; Jeffrey M Karp
Journal:  Blood       Date:  2011-10-27       Impact factor: 22.113

Review 5.  Multipotent mesenchymal stromal cells and the innate immune system.

Authors:  Katarina Le Blanc; Dimitrios Mougiakakos
Journal:  Nat Rev Immunol       Date:  2012-04-25       Impact factor: 53.106

Review 6.  Mesenchymal stem cells in the pathogenesis and therapy of breast cancer.

Authors:  Christelle P El-Haibi; Antoine E Karnoub
Journal:  J Mammary Gland Biol Neoplasia       Date:  2010-12-21       Impact factor: 2.673

Review 7.  Pluripotent stem cell heterogeneity and the evolving role of proteomic technologies in stem cell biology.

Authors:  Rebekah L Gundry; Paul W Burridge; Kenneth R Boheler
Journal:  Proteomics       Date:  2011-09-08       Impact factor: 3.984

8.  Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy.

Authors:  Christelle P El-Haibi; George W Bell; Jiangwen Zhang; Anthony Y Collmann; David Wood; Cally M Scherber; Eva Csizmadia; Odette Mariani; Cuihua Zhu; Antoine Campagne; Mehmet Toner; Sangeeta N Bhatia; Daniel Irimia; Anne Vincent-Salomon; Antoine E Karnoub
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-02       Impact factor: 11.205

9.  Cell-based therapies for regenerating bone.

Authors:  S B Goodman
Journal:  Minerva Ortop Traumatol       Date:  2013-04-01

10.  Neural stem cells improve intracranial nanoparticle retention and tumor-selective distribution.

Authors:  Rachael Mooney; Yiming Weng; Revathiswari Tirughana-Sambandan; Valerie Valenzuela; Soraya Aramburo; Elizabeth Garcia; Zhongqi Li; Margarita Gutova; Alexander J Annala; Jacob M Berlin; Karen S Aboody
Journal:  Future Oncol       Date:  2014-02       Impact factor: 3.404

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.